Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib Plus Rituximab in Indolent Mantle Cell Lymphoma
NCT05635162Phase 2Recruiting
- Sponsor
- University College London
- Start
- May 2024
- Primary completion
- Oct 2028
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of zanubrutinib in mantle cell lymphoma (MCL) (2 arms), sponsored by University College London. Primary endpoint: Event Free Survival up to 60 months. Started May 2024; status: recruiting.
02
Drugs
zanubrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT05635162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05635162.